TABLE 1.
Features of 1,282 patients
| ET JAK2 wild type |
ET JAK2V617F |
PV JAK2V617F |
p | ||
|---|---|---|---|---|---|
| Patients number | 376 | 491 | 415 | ||
| Laboratory features | |||||
| Age (years, median, range) | 49 (8 – 88) | 56 (12 – 93) | 61 (17 – 91) | <.0001† | |
| Gender, F/M (number, %) | 249/125 (67/33) | 338/155 (69/31) | 191/222 (46/54) | <.0001† | |
| Hemoglobin (g/dL, median, range) | 13.6 (9.7 –15) | 14.5 (8.9 – 15) | 17.6 (13 – 24) | <.0001† | |
| Hematocrit (%, median, range) | 41 (30 – 51.5) | 43 (30 – 54) | 53.8 (40 – 71.5) | <.0001† | |
| White Blood Cells (×109/L, median, range) |
8.3 (3.3 – 26) | 9.1 (4 – 35) | 10.5 (4.9 – 49.7) | <.0001† | |
| Platelets (×109/L, median, range) | 817 (407 – 2269) | 733 (304 – 2149) | 487 (112 – 1639) | <.0001† | |
| Quantitative JAK2V617F (%)* | |||||
| 0 | 376 (100) | - | - | ||
| 1–25 | 190 (49) | 64 (19) | |||
| 26–50 | 177 (45) | 118 (36) | |||
| >50 | 23 (6) | 147 (45) | <.0001‡ | ||
| Years from diagnosis to assay (median, range) |
- | 2.26 (0 – 24.8) | 1.32 (0 – 24.5) | 0.060† | |
| Evolutions (number, %) | 26 (7) | 51 (10.5) | 28 (7) | ||
| PV | 1 (0.5) § | 23 (5) | - | 0.004 ¶ | |
| MF | 24 (6) | 25 (5) | 25 (6) | 0.842‡ | |
| AML | 1 (0.5) | 3 (0.5) | 3 (1) | 0.568‡ | |
| Clinical features | |||||
| High-risk patients (number, %) | 136 (36) | 285 (58) | 248 (60) | <.0001‡ | |
| Previous Thrombosis (number, %) | 61 (16) | 132 (27) | 70 (17) | 0.003‡ | |
| IMA | 12 (3) | 40 (8) | 10 (2) | ||
| Ictus/TIA | 20 (5) | 36 (7) | 26 (7) | ||
| PAT | 8 (2) | 15 (3) | 1 (0) | ||
| VTE | 21 (6) | 41 (9) | 33 (8) | ||
*
Percentages calculated respectively on 390 and 329 ET and PV JAK2V617F patients, for whom quantitative determination was carried out
†
Wilcoxon rank-sum non-parametric test for trend
‡
Pearson extended chi-square test
¶
Fisher exact test
§
JAK2 persistently negative